Education
About Us
Working with TipRanks
Follow Us
Oculis Holding (OCS)
NASDAQ:OCS
OCS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$10.79 - $23.08
Previous CloseN/A
Volume95.89K
Average Volume (3M)45.07K
Market Cap
$853.44M
Enterprise Value$619.50M
Total Cash (Recent Filing)CHF46.28M
Total Debt (Recent Filing)CHF114.27M
Price to Earnings (P/E)―
Beta0.55
Next Earnings
May 08, 2025EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.39
Shares Outstanding48,000,000
10 Day Avg. Volume36,801
30 Day Avg. Volume45,072
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)854.93
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$35.00Price Target Upside95.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Oculis Holding News
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPrivosegtor has shown positive safety and efficacy data in the Phase 2 ACUITY trial for acute optic neuritis, with potential expansion into multiple sclerosis relapse and NAION, representing a significant market opportunity.
FDA AlignmentOculis believes that it now has alignment with the FDA on a precision medicine-based development approach, leveraging biomarker-driven patient selection.
Financial PositionThe recently completed $100m equity financing extends cash runway into early 2028.
Bears Say
Market PerceptionOculis's ophthalmology portfolio is considered underappreciated relative to peak sales.
Regulatory RisksRisks include possible failure of OCS-01 or OCS-02 in clinical trials or to secure regulatory approval, as well as potential dilution risk.
---
Ownership Overview
―
Insiders
0.03% Mutual Funds
0.18% Other Institutional Investors
99.76% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
OCS FAQ
What was Oculis Holding’s price range in the past 12 months?
Oculis Holding lowest stock price was $10.79 and its highest was $23.08 in the past 12 months.
What is Oculis Holding’s market cap?
Oculis Holding’s market cap is $853.44M.
When is Oculis Holding’s upcoming earnings report date?
Oculis Holding’s upcoming earnings report date is May 08, 2025 which is in 13 days.
How were Oculis Holding’s earnings last quarter?
Oculis Holding released its earnings results on Mar 11, 2025. The company reported -$0.819 earnings per share for the quarter, missing the consensus estimate of -$0.563 by -$0.255.
Is Oculis Holding overvalued?
According to Wall Street analysts Oculis Holding’s price is currently Undervalued.
Does Oculis Holding pay dividends?
Oculis Holding does not currently pay dividends.
What is Oculis Holding’s EPS estimate?
Oculis Holding’s EPS estimate is -0.52.
How many shares outstanding does Oculis Holding have?
Oculis Holding has 48,000,000 shares outstanding.
What happened to Oculis Holding’s price movement after its last earnings report?
Oculis Holding reported an EPS of -$0.819 in its last earnings report, missing expectations of -$0.563. Following the earnings report the stock price went up 2.391%.
Which hedge fund is a major shareholder of Oculis Holding?
Currently, no hedge funds are holding shares in OCS
---
Oculis Holding Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.00 (95.64% Upside)
$35.00 (95.64% Upside)
Hedge Fund Trend
Decreased
By 663.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
49.45%
12-Months-Change
Fundamentals
Return on Equity
-101.29%
Trailing 12-Months
Asset Growth
-2.26%
Trailing 12-Months
Company Description
Oculis Holding
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
---
OCS Stock 12 Month Forecast
Average Price Target
$35.00
▲(95.64% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
Ocular Therapeutix
―
Anavex Life Sciences
―
Mineralys Therapeutics, Inc.
―
Bicara Therapeutics Inc.
―
Best Analysts Covering OCS
1 Year
1 Year Success Rate
9/12 ratings generated profit
1 Year Average Return
+30.58%
reiterated a buy rating last month
Copying Colleen M. Kusy's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +30.58% per trade.
---